Shares of Alphatec Holdings cratered after the spine-surgery specialist missed third-quarter revenue expectations and slashed its full-year outlook, raising a pointed question: can a company growing surgical cases at 20% sustain investor confidence when its highest-margin product line is shrinking?
A $4 Million Miss That Erased $400 Million in Market Value
Alphatec posted $221.2 million in Q3 revenue, falling short of the $224.3 million Wall Street expected.
Management cut its full-year 2026 revenue guidance to roughly $862 million , well below FactSet's prior estimate of $882 million.
The stock plunged over 31% in premarket trading the next morning , wiping out roughly a quarter of the company's market capitalization in a single session. Trading volume surged to 27.3 million shares — nine times the daily average.
Biologics Are the Real Problem, Not Demand
Biologics revenue — the bone-graft materials surgeons use alongside Alphatec's hardware — declined $1 million year-over-year, dragging revenue per case down roughly 5%.
This matters because Alphatec's business model depends on hardware adoption pulling through high-margin proprietary biologics; when that "attachment rate" drops, each surgery generates less revenue.
Management expects biologics contribution to remain flat into Q4 , offering no near-term recovery signal.
The Margin Story Provides a Thin Silver Lining
Adjusted EBITDA — a rough proxy for operating cash profit — hit $38 million, up 46% year-over-year, with margins expanding over 400 basis points to 17%.
The company generated positive free cash flow for the fifth consecutive quarter and repaid its remaining 2026 convertible debt. But EBITDA margin guidance was also trimmed to 16% for the full year , dimming that bright spot.
Wall Street Is Divided on What Comes Next
BMO Capital Markets downgraded Alphatec to "market perform" with an $8 price target , while JPMorgan lowered its target from $16 to $15 but maintained an "overweight" (buy-equivalent) rating.
TD Cowen cut its target to $10 but also kept a "buy."
The stock is now down roughly 50% year-to-date , pricing in significant doubt that volume growth alone can compensate for weakening revenue per surgery. The Q4 biologics trajectory will determine whether this selloff was a buying opportunity or an early warning.